Sol-gel Technologies Ltd. · NASDAQ:SLGL
Sol-gel Technologies — Investor Presentation (February 2023)
19 slides from Sol-gel Technologies's investor presentation, Feb 2, 2023
Slide 1: Sol-Gel Advanced Topical Therapy
$ Sol- Gel ay nced Topical Therapy
Slide 2: Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not lim
Slide 3: Pioneering Topical Dermatological Drugs: Two FDA Approvals Within One Year
PIONEERING TOPICAL DERMATOLOGICAL DRUGS Two FDA Approvals Within One Year Not a real patient Not a real patient
Slide 4: TWYNEO for Acne Was Launched
Say hello to thisnever-before-seen combo TWYNEO® FOR ACNE WAS LAUNCHED First and only FDA Approved Fixed‑Dose Combination of Tretinoin and Benzoyl Peroxide
Slide 5: TWYNEO Offers Comprehensive Treatment for Acne Patients
TWYNEO® OFFERS COMPREHENSIVE TREATMENT FOR ACNE PATIENTS Potential to Become 1st Line Treatment Acne vulgaris is a multifactorial disease. Even though benzoyl peroxide and tretinoin are widely prescribed separately and have a complementary mechanism of action, so far, they could not be applied conco
Slide 6: Treating Severe Acne Patient with TWYNEO
* Individual results vary BASELINE “Severe”; 29 inflamed lesions 31 non-inflamed lesions; 1 nodule WEEK 12 “Moderate”; 9 inflamed lesions 5 non-inflamed lesions; No nodules TREATING SEVERE ACNE PATIENT WITH TWYNEO® Subject 507-003 || 18 Years Old | Female | White | Not Hispanic or Latino*
Slide 7: EPSOLAY for Inflammatory Lesions of Rosacea Was Launched
EPSOLAY® FOR INFLAMMATORY LESIONS OF ROSACEA WAS LAUNCHED First and only Benzoyl Peroxide in Rosacea Rosacea care with the brilliant touch of technology
Slide 8: EPSOLAY Offers Effective Topical Treatment for Rosacea Patients
EPSOLAY® OFFERS EFFECTIVE TOPICAL TREATMENT FOR ROSACEA PATIENTS Potential to Change Treatment Landscape Inflammatory lesions of rosacea resemble acne vulgaris, except that comedones (whiteheads and blackheads) are absent and only inflammatory lesions exist EPSOLAY contains encapsulated benzoyl pero
Slide 9: Treating Severe Rosacea Patient with EPSOLAY
BASELINE “Severe”; 31 inflamed lesions WEEK 2 “Clear”; No inflamed lesions “Clear”; No inflamed lesions WEEK 12 “Almost Clear”; 1 inflamed lesion WEEK 8 “Clear”; No inflamed lesions TREATING SEVERE ROSACEA PATIENT WITH EPSOLAY® Subject 116-009 || 41 Years Old | Female | White | Not Hispanic or Latin
Slide 10: Partnering with Market Leader Galderma
PARTNERING WITH MARKET LEADER GALDERMA Galderma has Heritage of Successful Drugs in Acne and Rosacea
Slide 11: Reaching Favorable Agreement with Galderma
REACHING FAVORABLE AGREEMENT WITH GALDERMA Option to Regain Commercialization Rights at No Cost 5 Years following 1st Sale $11 million in upfront and product approval payments Mid- to high-teen percentage of royalties on net sales Up to additional $9 million in sales milestone payments Option to reg
Slide 12: Implementing Innovation: Enabling Microencapsulation Technology
IMPLEMENTING INNOVATION Enabling Microencapsulation Technology Proprietary silica-based microencapsulation technology allows development of drugs that have the potential to be more effective and tolerable than existing drugs Core/shell structure designed to boost tolerability High encapsulation effi
Slide 13: Indication and Important Safety Information
Indication: TWYNEO® (tretinoin and benzoyl peroxide) Cream, 0.1%/3% is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with TWYNEO Cream were pain (s
Slide 14: Pursuing Leadership in Dermatology: Innovative Pipeline
PURSUING LEADERSHIP IN DERMATOLOGY Innovative Pipeline of Topical Skin Medications FDA Approved SGT-210 (topical erlotinib)Pachyonychia Congenita & other Rare Skin Indications SGT-610 (patidegib gel, 2%)Gorlin Syndrome Start H2/2023 FDA Approved Pre-clinical Phase 2 Phase 3 Filed Research Phase 1 U.
Slide 15: SGT-210 Aims to Reduce Hyperkeratosis Without Systemic Adverse Events
SGT-210 Aims to Reduce Hyperkeratosis Without Systemic Adverse Events Potentially first and only topical erlotinib Pachyonychia congenita is an example of a rare hyperkeratosis skin disorder inherited in an autosomal dominant fashion In this recent case report, orally-administered erlotinib improved
Slide 16: Sale of Generic Assets and Securing Non-Dilutive Funding
Sale of Generic Assets and Securing Non-Dilutive Funding Focusing on innovative pipeline Sale of Generic Assets to Padagis in November 2021 in return for $21.5M in quarterly installments over 24 months Proceed with 50/50 gross profit-sharing collaboration on 2 programs encompassing 4 generic drug ca
Slide 17: Securing a Strong Balance Sheet
SECURING A STRONG BALANCE SHEET Financial Profile $7.6M proceeds related to revenues from Padagis to be received in 2023 Financials December 31, 2022 Cash and Investments $33.6M Shares Outstanding 23,129,469 ordinary shares Expected Partnership Income Quarterly payments by Padagis; Royalties from Ga
Slide 18: Building Our Future: Investor Highlights
BUILDING OUR FUTURE Investor Highlights Completed development of EPSOLAY and TWYNEO and gained FDA approvals Maximized likelihood of market success for EPSOLAY and TWYNEO through commercialization agreements with US market leader, while retaining the option to regain commercialization rights 5 years
Slide 19: Sol-Gel Advanced Topical Therapy
$ Sol- Gel ay nced Topical Therapy
Sol-Gel Technologies — Investor Presentation (February 2023) on 6ix